/
BCTXZ
$0.08+$0.00 (+0.00%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.06 – $1.07
2% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
WARRANT
Price (6 mo)
Loading chart…
Change$-1.23
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $16.9K | $18.7K | $18.7K | $15.6K | $0 | $0 | $0 | $107.9K |
| Gross profit | −$16.9K | −$18.7K | −$18.7K | −$15.6K | $0 | $0 | $0 | −$107.9K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $3.1M | $4.9M | $3.0M | $2.0M | $8.0M | $15.3M | $27.2M | $21.5M |
| Operating income | −$5.0M | −$6.2M | −$4.8M | −$7.1M | −$15.3M | −$23.3M | −$33.3M | −$27.5M |
| EBITDA | −$5.0M | −$6.2M | −$4.8M | −$7.1M | −$26.8M | −$23.3M | −$4.8M | −$27.4M |
| Net income | −$5.4M | −$5.8M | −$4.9M | −$13.8M | −$26.8M | −$20.3M | −$4.8M | −$26.6M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1799.26 | -1497.36 | -1038.19 | -467.51 | -259.50 | -195.00 | -43.68 | -62.95 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $0.00 | $0.00–$0.00 | 0 |
| 2027 | $10M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$19.12
Price
$0.08
Implied upside
+23833%
Peer comparison
BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
www.briacell.com- Employees
- 4
- IPO / List date
- Apr 25, 2025
- HQ
- WEST VANCOUVER, A1
Held by traders on TradeandTell
No one on the platform currently holds BCTXZ.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BCTXZ as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BCTXZ yet.